brusatol has been researched along with Pancreatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, B; Huang, C; Huang, X; Lou, B; Xiang, Y; Ye, W; Yu, D; Zhang, J; Zhou, M | 1 |
| Chen, B; Chen, H; Deng, T; Huang, C; Lou, B; Shi, K; Xiang, Y; Ye, W; Yu, D; Zhang, F; Zhang, J; Zhou, M | 1 |
2 other study(ies) available for brusatol and Pancreatic Neoplasms
| Article | Year |
|---|---|
Brusatol inhibits growth and induces apoptosis in pancreatic cancer cells via JNK/p38 MAPK/NF-κb/Stat3/Bcl-2 signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quassins; STAT3 Transcription Factor; Tumor Cells, Cultured | 2017 |
Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-E2-Related Factor 2; Pancreatic Neoplasms; Quassins; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |